Provivi CEO and leadership

Mr. Peter Meinhold, Ph.D., serves as Chief Technology Officer of Provivi, Inc. Mr. Meinhold was a co-founder and Director of Research at Gevo, Inc. since 2005 until May 2013. He has 12 years of experience in research and development of biotechnology for fuels and chemicals production. For his thesis research, Mr. Meinhold engineered the fatty acid hydroxylating cytochrome P450 BM-3 into an alkane hydroxylating one that accepts substrates as short as ethane. In 2010, he was recognized by MIT’s Technology Review magazine as one of the world’s top innovators. He holds nine issued patents in the U.S. alone with dozens more pending. Mr. Meinhold received his Diploma (equivalent to a B.Sc.) in Biotechnology from the University of Applied Sciences Weihenstephan, Germany and a PhD in Biochemistry at the California Institute of Technology.

Paul Kuc joined Ceres in 2008 as Chief Financial Officer, following a 12-year career with Monsanto Company, where he held various regional and global finance positions, including posts in Argentina, Brazil, Canada, Mexico and the United States, with his last position, beginning April 2007, as Lead Worldwide Manufacturing Finance at Seminis, Inc., which was purchased by Monsanto in 2005. At Monsanto, among other responsibilities, he developed and implemented international costing and financial systems for the seed and agricultural biotechnology company. Mr. Kuc began his career, from June 1994 to June 1996 at the pharmaceutical company Eli Lilly and Company. He holds a Master’s of Science degree in Economics from the University of Lodz, Poland and an M.B.A. from the Ivey Business School, University of Western Ontario, Canada.

Mr. Peter Meinhold, Ph.D., serves as Chief Technology Officer of Provivi, Inc. Mr. Meinhold was a co-founder and Director of Research at Gevo, Inc. since 2005 until May 2013. He has 12 years of experience in research and development of biotechnology for fuels and chemicals production. For his thesis research, Mr. Meinhold engineered the fatty acid hydroxylating cytochrome P450 BM-3 into an alkane hydroxylating one that accepts substrates as short as ethane. In 2010, he was recognized by MIT’s Technology Review magazine as one of the world’s top innovators. He holds nine issued patents in the U.S. alone with dozens more pending. Mr. Meinhold received his Diploma (equivalent to a B.Sc.) in Biotechnology from the University of Applied Sciences Weihenstephan, Germany and a PhD in Biochemistry at the California Institute of Technology.

Paul Kuc joined Ceres in 2008 as Chief Financial Officer, following a 12-year career with Monsanto Company, where he held various regional and global finance positions, including posts in Argentina, Brazil, Canada, Mexico and the United States, with his last position, beginning April 2007, as Lead Worldwide Manufacturing Finance at Seminis, Inc., which was purchased by Monsanto in 2005. At Monsanto, among other responsibilities, he developed and implemented international costing and financial systems for the seed and agricultural biotechnology company. Mr. Kuc began his career, from June 1994 to June 1996 at the pharmaceutical company Eli Lilly and Company. He holds a Master’s of Science degree in Economics from the University of Lodz, Poland and an M.B.A. from the Ivey Business School, University of Western Ontario, Canada.

An enterprising, forward-thinking TOP EXECUTIVE AND CORPORATE OFFICER, with profit and loss responsibility as well as extensive experience in sales and marketing, business development, product development, financial management, and strategic planning. As a results-driven leader, identifies opportunities to improve operations, optimize performance, and reduce cost. Possesses a demonstrated ability to maximize the returns from the development, manufacture, introduction, marketing, and sales of proprietary and non-proprietary products to the public and private markets.

Specialties: Proprietary product sales and marketing, team building of diverse groups of people, profit maximization, cost management in relation to revenue growth.